LEVERKUSEN, Germany, July 10, 2026
Bayer AG has announced a landmark €3.0 billion equity investment agreement with global asset management firm Apollo to strengthen its capital structure while maintaining full operational control of its long-acting reversible contraceptives (LARC) business. Under the agreement, Apollo-managed funds and affiliates will acquire a minority, non-controlling stake in a newly established entity that will hold Bayer’s global LARC portfolio. Bayer will retain a majority ownership position, continue to oversee all commercial and operational activities, and keep the business fully integrated within its Pharmaceuticals Division. The strategic transaction provides Bayer with additional financial flexibility to support long-term business priorities while reinforcing its commitment to women’s healthcare and pharmaceutical innovation. The investment also reflects growing confidence in the long-term value of Bayer’s reproductive health portfolio and demonstrates how innovative financing structures can support sustainable growth without compromising strategic business control.
Strategic Investment Strengthens Bayer’s Financial Position
The €3 billion transaction has been structured to improve Bayer’s capital structure while preserving ownership and operational leadership of one of its important pharmaceutical businesses. According to the agreement, Apollo will invest equity into a dedicated entity containing Bayer’s LARC portfolio, while Bayer will continue to hold a controlling interest and remain responsible for all operational, commercial, manufacturing, and strategic decisions. Company executives stated that the transaction enhances financial flexibility during a period of increased liquidity requirements associated with bond maturities and ongoing legal obligations.
Importantly, Bayer confirmed that no changes will be made to its LARC business strategy, research activities, product commercialization, or day-to-day operations. The business will remain fully consolidated within Bayer’s financial statements, ensuring continuity for customers, healthcare providers, and global stakeholders.
Apollo Supports Long-Term Pharmaceutical Growth
Advertisement
For Apollo, the investment represents another example of its strategy to provide customized capital solutions to established global corporations while enabling them to maintain operational independence. Apollo executives described Bayer as a global life sciences leader with a strong pharmaceutical portfolio and emphasized that the transaction aligns with the firm’s focus on delivering flexible financing solutions that strengthen corporate balance sheets without requiring operational control.
By taking only a minority, non-controlling interest, Apollo gains exposure to a stable healthcare business while allowing Bayer to continue executing its long-term pharmaceutical strategy. The transaction also demonstrates increasing collaboration between global investment firms and life sciences companies seeking alternative financing models that support innovation, commercialization, and sustainable growth without divesting strategically important assets.
Transaction Reinforces Bayer’s Women’s Health Strategy
Bayer’s long-acting reversible contraceptives portfolio remains a core component of the company’s global women’s health business, providing innovative reproductive healthcare solutions used by millions of women worldwide. The company emphasized that the investment will not alter product availability, commercial operations, manufacturing activities, or future development plans for the LARC franchise. Subject to customary regulatory approvals, including antitrust clearance, the transaction is expected to close during the third quarter of 2026.
Beyond strengthening Bayer’s balance sheet, the agreement illustrates how innovative financial partnerships can provide capital for future pharmaceutical investment while preserving strategic control over high-value healthcare businesses. As Bayer continues investing in pharmaceutical innovation, women’s health, and long-term portfolio growth, the Apollo partnership positions the company to maintain financial resilience while continuing to deliver advanced therapies and healthcare solutions across global markets.
Source: Bayer, Apollo press release
